MATTHEW W FOEHR
CIK 1237556 · President and CEO · last filed 2026-04-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$53.00M
Companies
6
Total Filings
134
Lifetime Open-Market Net
-$24.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OABIW | President and CEO | 4,420,492 | $0.08 | $368.7K | $7.27M | 33 | 2026-04-07 |
| VKTX | Director | 135,186 | $33.86 | $4.58M | -$286.7K | 11 | 2026-01-05 |
| LGND | President and COO | 162,187 | $296.28 | $48.05M | -$31.25M | 58 | 2022-11-03 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | Director | 46,250 | $4.60 | $212.7K | -$79.9K | 8 | 2021-03-25 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Director | 5,545 | — | — | $133.1K | 12 | 2020-04-23 |
| Viking Therapeutics, Inc. (VKTX.W) Delisted | Director | 26,250 | — | — | $24.8K | 1 | 2016-04-13 |
Recent Filings · Page 2 of 14
134 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-14 | VKTX | Exer (M) | +20,786 | $166.3K | EDGAR |
| 2025-04-07 | OABI | Notice (144) | −19,382 | -$38.7K | EDGAR |
| 2025-04-07 | OABIW | Mixed | +17,076 | -$38.8K | EDGAR |
| 2025-02-19 | OABIW | Mixed | +29,521 | -$123.0K | EDGAR |
| 2025-02-18 | OABI | Notice (144) | −13,964 | -$51.4K | EDGAR |
| 2025-01-22 | OABIW | Mixed | +35,192 | -$135.5K | EDGAR |
| 2025-01-21 | OABI | Notice (144) | −41,811 | -$135.4K | EDGAR |
| 2025-01-06 | VKTX | Grant (A) | — | $0 | EDGAR |
| 2024-12-10 | OABIW | Mixed | +12,921 | -$56.3K | EDGAR |
| 2024-12-09 | OABI | Notice (144) | −13,634 | -$56.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.